Thyroid cancer is usually treated with surgical intervention followed by ablative radiotherapy if indicated to eliminate any metastases. Five-year survival rates are 99% for papillary thyroid carcinoma (PTC) and 82% for medullary thyroid carcinoma (MTC). The chances of survival decrease significantly with two simultaneous types of cancers and with male gender. PTC and MTC present as different entities. The coexistence of different types of thyroid carcinoma in a patient is a rare event. We report the case of a 45-year-old Saudi male with a rare synchronous occurrence of PTC in the thyroid gland, along with ectopic MTC with a unique prognosis over the years. Our case adds data to the literature supporting the coincidental coexistence of PTC and MTC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663066 | PMC |
| http://dx.doi.org/10.1093/jscr/rjad625 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thy1c Cytology Is a Reliable Method of Excluding Thyroid Cancer in Dominant Cystic Nodules.
Cytopathology
January 2025
Department of Endocrine Surgery, University Hospital of Wales, Cardiff, UK.
Background: Traditional teaching dictated that patients with recurrent thyroid cysts undergo excision owing to a 12% risk malignancy. Ultrasound evaluation now determines management of these patients augmented by fine needle biopsy. In UK, a non-diagnostic category for thyroid cysts (Thy1c) exists, whereas the Bethesda system combines 'non-diagnostic-cyst fluid only' into Category I along with paucicellular and acellular results.
View Article and Find Full Text PDFBackground And Aims: Non-Alcoholic Steatohepatitis (NASH), a severe form of Non-Alcoholic Fatty Liver Disease (NAFLD), is characterized by inflammation and fibrosis in the liver, often progressing to cirrhosis and hepatocellular carcinoma. Despite its rising prevalence and significant disease burden, effective pharmacological treatments have been limited to lifestyle modifications and surgical interventions. Recently, resmetirom, a thyroid hormone receptor-β agonist, received FDA approval for treating NASH, offering new hope to patients.
View Article and Find Full Text PDFTHE EVALUATION OF SHORT AND LONG-TERM QUALITY OF LIFE IN PATIENTS UNDERGOING THYROIDECTOMY DUE TO BENIGN OR MALIGNANT DISEASES.
Acta Endocrinol (Buchar)
January 2025
Health Sciences University "Dr. Abdurrahman Yurtaslan" Oncology Training and Research Hospital, Department of General Surgery, Ankara, Turkey.
Context: In patients undergoing thyroidectomy for malignant disease, lower quality of life scores were observed in the early postoperative period compared to those undergoing thyroidectomy for benign causes.
Objective: Thyroid gland diseases are commonly encountered in society. This study presents health-related quality of life differences in thyroidectomies performed for benign and malignant diseases and the factors affecting this.
ONCOCYTIC VARIANT OF MEDULLARY CARCINOMA THYROID - A RARE ENTITY.
Acta Endocrinol (Buchar)
January 2025
AIIMS Mangalagiri - Pathology, Mangalagiri, Guntur, Andhra Pradesh, Vijayawada, India.
EFFICACY AND PROGNOSIS IN PATIENTS WITH PAPILLARY THYROID CANCER WITH POSTOPERATIVE PREABLATIVE STIMULATED THYROGLOBULIN ABOVE 10 NG/ML AFTER INITIAL THERAPY WITH RADIOIODINE.
Acta Endocrinol (Buchar)
January 2025
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China - Department of Nuclear Medicine, Hefei, Anhui, China.
Objective: Few prognostic analyses have been conducted for papillary thyroid cancer (PTC) patients with preablative stimulated Tg >10 ng/mL. We investigated the therapeutic responses and prognosis of these patients after the initial radioiodine (RAI) therapy.
Methods: We retrospectively assessed 256 patients with PTC who underwent RAI remnant ablation after total thyroidectomy, and all presTg levels were >10 ng/mL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!